Affiliation:
1. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University,
Phitsanulok, Thailand
2. Center of Excellence for Environmental Health and Toxicology, Naresuan
University, Phitsanulok, Thailand
Abstract
Abstract:
Atypical antipsychotic quetiapine (QTP) exhibits high pharmacokinetic variability
and population pharmacokinetic (PopPK) analysis is one of the approaches used to characterize
factors influencing QTP pharmacokinetic variability. Though QTP is not regarded as a narrow
therapeutic index drug, knowledge of this area is of importance. Thus, this review was conducted
to summarize significant predictors for QTP pharmacokinetic variability identified using
a PopPK analysis and to explore any knowledge gaps to be investigated. PubMed, Scopus,
and CINAHL Complete databases were searched for eligible studies, and 75 articles were identified.
Of these, only five studies were included as they were conducted using a nonlinear
mixed-effects approach. This review found that only limited predictors for QTP pharmacokinetics
were identified, with body weight being a predictor for the volume of distribution and
age and γ-glutamyl transpeptidase being predictors for QTP clearance. None of the studies included
elderly patients aged >65 years, and thus factors associated with aging were not investigated.
Also, most of the participants in the PopPK analyses were from clinical trials which
might not reflect real-world patients e.g., the impacts of polypharmacy may not be available.
Moreover, while a population pharmacokinetic-pharmacodynamic model explaining QTP exposure
and clinical response using the scores of the Brief Psychiatric Rating Scale is available,
knowledge relevant to the relationship between exposure and QTP side effects has not been
explored. Based on this limited information, future PopPK research encompassing a wide range
of patient characteristics is required.
Publisher
Bentham Science Publishers Ltd.
Subject
Psychiatry and Mental health